Characterizing the original anti‐C5 function‐blocking antibody, BB5.1, for species specificity, mode of action and interactions with C5

Development and characterisation of novel anti‐C5 monoclonal antibodies capable of inhibiting complement in multiple species

(2019) Wioleta M. Zelek et al.   IMMUNOLOGY

Compendium of current complement therapeutics

(2019) Wioleta M Zelek et al.   MOLECULAR IMMUNOLOGY

Extracting the barbs from complement assays: Identification and optimisation of a safe substitute for traditional buffers

(2018) Wioleta M. Zelek et al.   IMMUNOBIOLOGY

Characterising a pH-switch anti-C5 antibody as a tool for human and mouse complement C5 purification and cross-species inhibition of classical and reactive lysis

(2018) Wioleta M. Zelek et al.   IMMUNOLOGY

SWISS-MODEL: homology modelling of protein structures and complexes

(2018) Andrew Waterhouse et al.   NUCLEIC ACIDS RESEARCH

Specific Inhibition of Complement Activation Significantly Ameliorates Autoimmune Blistering Disease in Mice

(2018) Sidonia Mihai et al.   Frontiers in Immunology

Developments in anti-complement therapy; from disease to clinical trial

(2018) Claire L. Harris et al.   MOLECULAR IMMUNOLOGY

Routes for Drug Translocation Across the Blood-Brain Barrier: Exploiting Peptides as Delivery Vectors

(2017) Mie Kristensen et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal Pathway

(2016) Janus Asbjørn Schatz-Jakobsen et al.   JOURNAL OF IMMUNOLOGY

Early Terminal Complement Blockade and C6 Deficiency Are Protective in EnterohemorrhagicEscherichia coli–Infected Mice

(2016) Ida Arvidsson et al.   JOURNAL OF IMMUNOLOGY

ABodyBuilder: Automated antibody structure prediction with data–driven accuracy estimation

(2016) Jinwoo Leem et al.   mAbs

Eculizumab epitope on complement C5: Progress towards a better understanding of the mechanism of action

(2016) Guillaume Brachet et al.   MOLECULAR IMMUNOLOGY

Structural basis for therapeutic inhibition of complement C5

(2016) Matthijs M Jore et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Structural basis for therapeutic inhibition of complement C5

(2016) Matthijs M Jore et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Stratification of responders towards eculizumab using a structural epitope mapping strategy

(2016) Anna-Luisa Volk et al.   Scientific Reports

Complement, a target for therapy in inflammatory and degenerative diseases

(2015) B. Paul Morgan et al.   NATURE REVIEWS DRUG DISCOVERY

Improving B-cell epitope prediction and its application to global antibody-antigen docking

(2014) Konrad Krawczyk et al.   BIOINFORMATICS

Genetic Variants in C5 and Poor Response to Eculizumab

(2014) Jun-ichi Nishimura et al.   NEW ENGLAND JOURNAL OF MEDICINE

GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit

(2013) Sander Pronk et al.   BIOINFORMATICS

Complement therapy in atypical haemolytic uraemic syndrome (aHUS)

(2013) Edwin K.S. Wong et al.   MOLECULAR IMMUNOLOGY

Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies

(2012) Julien Zuber et al.   Nature Reviews Nephrology

Anti-Complement Component C5 mAb Synergizes with CTLA4Ig to Inhibit Alloreactive T cells and Prolong Cardiac Allograft Survival in Mice

(2011) H. Raedler et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis

(2011) Bianca Woehrl et al.   JOURNAL OF CLINICAL INVESTIGATION

Cobra venom factor: Structure, function, and humanization for therapeutic complement depletion

(2010) Carl-Wilhelm Vogel et al.   TOXICON

Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis

(2009) D. A. Copland et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY